Riociguat Reduces Pulmonary

Arterial Hypertension in

Hypoxia-Semaxanib

Intervention Model

1

Additional data demonstrating intervention effect of riociguat and

sildenafil against established PAH development in most relevant

preclinical model

Hypoxia + SU5416

- administer SU5416, then place animals into hypoxia

environment for 28 days

- at Day 28, remove from hypoxia and begin intervention

treatment with either vehicle, riociguat, sildenafil

- measure pulmonary hemodynamics and right ventricular

hypertrophy at Day 56

- On Day 56, animals were instrumented for measurement of

pulmonary arterial pressure and right ventricular hypertrophy

- Riociguat and sildenafil rats were compared against hypoxia/SU5416

vehicle treatments

- Riociguat and sildenafil significantly intervene against

established PAH in the 8 week hypoxia/SU5416 rat model

0

20

40

60

80

100

120

Syst

olic

Pu

lmo

nar

y A

rte

rial

Pre

ssu

re

(mm

Hg)

Vehicle

Sildenafil 60 mg/kg

Riociguat 10 mg/kg

0.000

0.100

0.200

0.300

0.400

0.500

0.600

0.700

Fult

on

's In

de

x R

V/(

LV+S

)

Vehicle

Sildenafil 60 mg/kg

Riociguat 10 mg/kg